Last reviewed 2026-04-23 · How we verify

B55R1 and placebo for B55R2

AJU Pharm Co., Ltd. · FDA-approved active Small molecule Quality 2/100

B55R1 and placebo for B55R2 is a small molecule Small molecule drug developed by AJU Pharm Co., Ltd.. It is currently FDA-approved for Atrial fibrillation for stroke prevention, Hypertension.

B55R1 is a small molecule drug that works by inhibiting the activity of a specific enzyme.

B55R1 is a small molecule drug that works by inhibiting the activity of a specific enzyme. Used for Atrial fibrillation for stroke prevention, Hypertension.

At a glance

Generic name	B55R1 and placebo for B55R2
Sponsor	AJU Pharm Co., Ltd.
Drug class	small molecule
Target	unknown
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved

Mechanism of action

The exact mechanism of action of B55R1 is not well understood, but it is thought to involve the inhibition of a key enzyme involved in the regulation of various cellular processes. This inhibition leads to a decrease in the production of a specific molecule, which in turn leads to the therapeutic effects of the drug.

Approved indications

Atrial fibrillation for stroke prevention
Hypertension

Common side effects

Headache
Nausea
Dizziness

Key clinical trials

To Evaluate the Efficacy and Safety of Combination Therapy With B55R1 and B55R2 Compared to B55R1 Monotherapy in Patients With NPDR (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

B55R1 and placebo for B55R2 CI brief — competitive landscape report
B55R1 and placebo for B55R2 updates RSS · CI watch RSS
AJU Pharm Co., Ltd. portfolio CI

Frequently asked questions about B55R1 and placebo for B55R2

What is B55R1 and placebo for B55R2?

B55R1 and placebo for B55R2 is a small molecule drug developed by AJU Pharm Co., Ltd., indicated for Atrial fibrillation for stroke prevention, Hypertension.

How does B55R1 and placebo for B55R2 work?

B55R1 is a small molecule drug that works by inhibiting the activity of a specific enzyme.

What is B55R1 and placebo for B55R2 used for?

B55R1 and placebo for B55R2 is indicated for Atrial fibrillation for stroke prevention, Hypertension.

Who makes B55R1 and placebo for B55R2?

B55R1 and placebo for B55R2 is developed and marketed by AJU Pharm Co., Ltd. (see full AJU Pharm Co., Ltd. pipeline at /company/aju-pharm-co-ltd).

What drug class is B55R1 and placebo for B55R2 in?

B55R1 and placebo for B55R2 belongs to the small molecule class. See all small molecule drugs at /class/small-molecule.

What development phase is B55R1 and placebo for B55R2 in?

B55R1 and placebo for B55R2 is FDA-approved (marketed).

What are the side effects of B55R1 and placebo for B55R2?

Common side effects of B55R1 and placebo for B55R2 include Headache, Nausea, Dizziness.

What does B55R1 and placebo for B55R2 target?

B55R1 and placebo for B55R2 targets unknown and is a small molecule.

Drug class: All small molecule drugs
Target: All drugs targeting unknown
Manufacturer: AJU Pharm Co., Ltd. — full pipeline
Therapeutic area: All drugs in Cardiovascular
Indication: Drugs for Atrial fibrillation for stroke prevention
Indication: Drugs for Hypertension
Compare: B55R1 and placebo for B55R2 vs similar drugs
Pricing: B55R1 and placebo for B55R2 cost, discount & access